Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 01:05 pm IST
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 339.06 million compared to TWD 465.73 million a year ago. Net income was TWD 11.83 million compared to TWD 120.7 million a year ago. Basic earnings per share from continuing operations was TWD 0.15 compared to TWD 1.56 a year ago. Diluted earnings per share from continuing operations was TWD 0.15 compared to TWD 1.54 a year ago.
For the nine months, sales was TWD 1,630.95 million compared to TWD 1,574.67 million a year ago. Net income was TWD 220.68 million compared to TWD 396.26 million a year ago. Basic earnings per share from continuing operations was TWD 2.85 compared to TWD 5.11 a year ago. Diluted earnings per share from continuing operations was TWD 2.82 compared to TWD 5.05 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
